Koninklijke Philips (NYSE:PHG) Upgraded by Wall Street Zen to Buy Rating

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

Separately, Sanford C. Bernstein raised shares of Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy".

Koninklijke Philips Stock Performance

Shares of PHG opened at $24.01 on Friday. The firm has a market cap of $23.12 billion, a PE ratio of 55.84, a PEG ratio of 0.70 and a beta of 0.76. The stock's fifty day moving average price is $23.59 and its two-hundred day moving average price is $24.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.28 and a quick ratio of 0.79. Koninklijke Philips has a 1 year low of $20.61 and a 1 year high of $31.57.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The technology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.13. Koninklijke Philips had a return on equity of 10.97% and a net margin of 2.11%. The business had revenue of $4.31 billion for the quarter, compared to analysts' expectations of $4.10 billion. During the same period in the previous year, the business posted $0.21 EPS. The firm's quarterly revenue was down 1.0% compared to the same quarter last year. On average, equities research analysts forecast that Koninklijke Philips will post 1.63 EPS for the current year.

Institutional Trading of Koninklijke Philips

A number of hedge funds and other institutional investors have recently made changes to their positions in PHG. Colonial Trust Co SC increased its position in shares of Koninklijke Philips by 724.0% during the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock valued at $36,000 after buying an additional 1,238 shares during the period. Bessemer Group Inc. increased its holdings in Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company's stock worth $51,000 after acquiring an additional 1,908 shares during the period. Farther Finance Advisors LLC increased its holdings in Koninklijke Philips by 37.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company's stock worth $54,000 after acquiring an additional 582 shares during the period. Millstone Evans Group LLC bought a new stake in Koninklijke Philips during the 4th quarter worth approximately $60,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Koninklijke Philips by 1,170.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company's stock worth $62,000 after acquiring an additional 2,247 shares during the period. 13.67% of the stock is currently owned by institutional investors.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.